8:30pm (EST) One of my favorite trades is the “history repeats itself” trade. These are trades on stocks that you actively follow and you know how to play them on the way up AND on the way down. One such trade that has fit that bill again is American InternationalRead more
AIG Takes a Beatdown
Market's Woes Continue
Amgen Looking to Open Higher
Weekly Wrap for 3/22/09
1. Commentary 2. Take-Two Revisited 3. Is Dendreon Headed for Double Digits? 4. Earnings 5. Current Trades 6. Monday Morning Playbook 7. Closing Thoughts ************************************************** 1. Commentary The market got off to a good start last week but struggled to hold onto gains by the end of a five-day workRead more
Weekly Wrap for 3/8/09
1. Commentary 2. Bounce or No Bounce? 3. Apollo Group Heads Lower 4. Earnings 5. Current Trades 6. Monday Morning Playbook (Take-Two) 7. Closing Thoughts ************************************************** 1. Commentary The market took another pounding for the week as all three indexes lost between 6%-7%. There was a flurry of expected andRead more
Amgen Aching
Amgen Stopped Out
Yeap, I jinxed us. In fact, I jinxed the entire market. I had mentioned Amgen’s (AMGN, $57.41, down $1.33) eight-day winning streak yesterday and that quickly came to a halt just like the rest of the market’s momentum. The March 60 calls (YAACL, $1.70, down $0.50) were recommended on FebruaryRead more
Weekly Wrap for 2/8/09
1. Commentary 2. Straddle’s Part 2 (Amazon Keeps on Rolling) 3. Financial Sector (open positions) 4. Akamai Technologies 5. Current Trades 6. Earnings 7. Closing Thoughts ************************************************** 1. Commentary The market had an outstanding week and it has been a minute since I have said that. For all of theRead more
Wednesday Morning Update
Biotech Grumblings
Genentech (DNA, $82.10, up $0.86) came out with some great news yesterday after the bell and said a late-stage study combining Avastin with Tarceva to treat lung cancer was a huge success. Tarceva is a drug from OSI Pharmaceutical’s (OSIP, $36.39, up $0.79) pipeline and is marketed by Genentech. TheRead more